Evidence map›Paper›PMID 41648641›Full record

ArticleFood science & nutrition2026

High Bioavailability Resveratrol Delivery System: A Novel Nutritional Strategy for the Prevention and Alleviation of Rheumatoid Arthritis.

Chenchen Yu, Chungang Zhang

Abstract read
In one paragraph

Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chenchen YuCollege of Pharmacy Liaoning University of Traditional Chinese Medicine Dalian China.
Chungang ZhangCollege of Pharmacy Liaoning University of Traditional Chinese Medicine Dalian China.ORCID https://orcid.org/0009-0001-0812-9576

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to develop an oral solid dispersion nutrient delivery system of resveratrol (RSV) and Eudragit E PO (E PO) for the prevention of rheumatoid arthritis. The RSV-E PO solid dispersion, prepared by the solvent method at a drug-polymer ratio of 1:7 (w/w), turned resveratrol into an amorphous state, as proved by SEM, DSC, XRD, and FTIR. Over 80% of resveratrol was released in vitro, a 13-fold increase compared to raw resveratrol. In male Sprague-Dawley rats, its oral administration (20 mg·kg

Indexed as

bioavailabilityresveratrolrheumatoid arthritissolid dispersion

Identifiers

PMID41648641
PMCPMC12872117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.